There has been increasing interest in the role played by B cells, plasma cells and their
associated antibody in the immune response to an allograft, driven by the need to undertake
antibody-incompatible transplantation and evidence suggesting that B cells play a role in
acute cellular rejection and in acute and chronic antibody-mediated rejection. A number of
immunosuppressive agents have emerged which target B cells, plasma cells and/or
antibody, for example, the B cell-depleting CD20 antibody rituximab. This review describes …